A decade of advances in human gut microbiome-derived biotherapeutics
Nature Microbiology · 08.01.2025 · 10 (2) · 301-312
DOI: 10.1038/s41564-024-01896-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Microbiology, online erschienen am 08.01.2025. Verfasst von Alena L Pribyl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Microba Life Sciences, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Biological Therapy. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 131 Literaturangaben.
Abstract (Originalsprache)
Microbiome science has evolved rapidly in the past decade, with high-profile publications suggesting that the gut microbiome is a causal determinant of human health. This has led to the emergence of microbiome-focused biotechnology companies and pharmaceutical company investment in the research and development of gut-derived therapeutics. Despite the early promise of this field, the first generation of microbiome-derived therapeutics (faecal microbiota products) have only recently been approved for clinical use. Next-generation therapies based on readily culturable and as-yet-unculturable colonic bacterial species (with the latter estimated to comprise 63% of all detected species) have not yet progressed to pivotal phase 3 trials. This reflects the many challenges involved in developing a new class of drugs in an evolving field. Here we discuss the evolution of the live biotherapeutics field over the past decade, from the development of first-generation products to the emergence of rationally designed second- and third-generation live biotherapeutics. Finally, we present our outlook for the future of this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Microba Life Sciences, Brisbane, Queensland, Australia.
- The University of Queensland, School of Chemistry and Molecular Biosciences, Australian Centre for Ecogenomics, Brisbane, Queensland, Australia. p.hugenholtz@uq.edu.au.
- Sitala Bio, Cambridge, UK. m.cooper@sitala.com.
Zitieren
APA
Pribyl, A. L., Hugenholtz, P., & Cooper, M. A. (2025). A decade of advances in human gut microbiome-derived biotherapeutics. Nature Microbiology, 10(2), 301-312. https://doi.org/10.1038/s41564-024-01896-3
Vancouver
Pribyl AL, Hugenholtz P, Cooper MA. A decade of advances in human gut microbiome-derived biotherapeutics. Nature Microbiology. 2025;10(2):301-312. doi:10.1038/s41564-024-01896-3
BibTeX
@article{Pribyl2025,
author = {Pribyl, Alena L and Hugenholtz, Philip and Cooper, Matthew A},
title = {A decade of advances in human gut microbiome-derived biotherapeutics},
journal = {Nature Microbiology},
year = {2025},
volume = {10},
number = {2},
pages = {301--312},
doi = {10.1038/s41564-024-01896-3}
}
EUVIMED